Cargando…

Novel Therapeutic Approaches in the Management of Chronic Kidney Disease

Chronic kidney disease (CKD) is a progressive and incurable disease that impairs kidney function. Its prevalence is estimated to affect up to 800 million individuals within the general population, and patients with diabetes and hypertension are particularly at risk. This disorder disrupts the physio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dąbek, Bartłomiej, Dybiec, Jill, Frąk, Weronika, Fularski, Piotr, Lisińska, Wiktoria, Radzioch, Ewa, Młynarska, Ewelina, Rysz, Jacek, Franczyk, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604464/
https://www.ncbi.nlm.nih.gov/pubmed/37893119
http://dx.doi.org/10.3390/biomedicines11102746
_version_ 1785126841733873664
author Dąbek, Bartłomiej
Dybiec, Jill
Frąk, Weronika
Fularski, Piotr
Lisińska, Wiktoria
Radzioch, Ewa
Młynarska, Ewelina
Rysz, Jacek
Franczyk, Beata
author_facet Dąbek, Bartłomiej
Dybiec, Jill
Frąk, Weronika
Fularski, Piotr
Lisińska, Wiktoria
Radzioch, Ewa
Młynarska, Ewelina
Rysz, Jacek
Franczyk, Beata
author_sort Dąbek, Bartłomiej
collection PubMed
description Chronic kidney disease (CKD) is a progressive and incurable disease that impairs kidney function. Its prevalence is estimated to affect up to 800 million individuals within the general population, and patients with diabetes and hypertension are particularly at risk. This disorder disrupts the physiological mechanisms of the body, including water and electrolyte balance, blood pressure regulation, the excretion of toxins, and vitamin D metabolism. Consequently, patients are exposed to risks such as hyperkalemia, hyperphosphatemia, metabolic acidosis, and blood pressure abnormalities. These risks can be reduced by implementing appropriate diagnostic methods, followed by non-pharmacological (such as physical activity, dietary, and lifestyle adjustment) and pharmacological strategies after diagnosis. Selecting the appropriate diet and suitable pharmacological treatment is imperative in maintaining kidney function as long as possible. Drugs such as finerenone, canakinumab, and pentoxifylline hold promise for improved outcomes among CKD patients. When these interventions prove insufficient, renal replacement therapy becomes essential. This is particularly critical in preserving residual renal function while awaiting renal transplantation or for patients deemed ineligible for such a procedure. The aim of this study is to present the current state of knowledge and recent advances, providing novel insights into the treatment of chronic kidney disease.
format Online
Article
Text
id pubmed-10604464
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106044642023-10-28 Novel Therapeutic Approaches in the Management of Chronic Kidney Disease Dąbek, Bartłomiej Dybiec, Jill Frąk, Weronika Fularski, Piotr Lisińska, Wiktoria Radzioch, Ewa Młynarska, Ewelina Rysz, Jacek Franczyk, Beata Biomedicines Review Chronic kidney disease (CKD) is a progressive and incurable disease that impairs kidney function. Its prevalence is estimated to affect up to 800 million individuals within the general population, and patients with diabetes and hypertension are particularly at risk. This disorder disrupts the physiological mechanisms of the body, including water and electrolyte balance, blood pressure regulation, the excretion of toxins, and vitamin D metabolism. Consequently, patients are exposed to risks such as hyperkalemia, hyperphosphatemia, metabolic acidosis, and blood pressure abnormalities. These risks can be reduced by implementing appropriate diagnostic methods, followed by non-pharmacological (such as physical activity, dietary, and lifestyle adjustment) and pharmacological strategies after diagnosis. Selecting the appropriate diet and suitable pharmacological treatment is imperative in maintaining kidney function as long as possible. Drugs such as finerenone, canakinumab, and pentoxifylline hold promise for improved outcomes among CKD patients. When these interventions prove insufficient, renal replacement therapy becomes essential. This is particularly critical in preserving residual renal function while awaiting renal transplantation or for patients deemed ineligible for such a procedure. The aim of this study is to present the current state of knowledge and recent advances, providing novel insights into the treatment of chronic kidney disease. MDPI 2023-10-11 /pmc/articles/PMC10604464/ /pubmed/37893119 http://dx.doi.org/10.3390/biomedicines11102746 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dąbek, Bartłomiej
Dybiec, Jill
Frąk, Weronika
Fularski, Piotr
Lisińska, Wiktoria
Radzioch, Ewa
Młynarska, Ewelina
Rysz, Jacek
Franczyk, Beata
Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
title Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
title_full Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
title_fullStr Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
title_full_unstemmed Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
title_short Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
title_sort novel therapeutic approaches in the management of chronic kidney disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604464/
https://www.ncbi.nlm.nih.gov/pubmed/37893119
http://dx.doi.org/10.3390/biomedicines11102746
work_keys_str_mv AT dabekbartłomiej noveltherapeuticapproachesinthemanagementofchronickidneydisease
AT dybiecjill noveltherapeuticapproachesinthemanagementofchronickidneydisease
AT frakweronika noveltherapeuticapproachesinthemanagementofchronickidneydisease
AT fularskipiotr noveltherapeuticapproachesinthemanagementofchronickidneydisease
AT lisinskawiktoria noveltherapeuticapproachesinthemanagementofchronickidneydisease
AT radziochewa noveltherapeuticapproachesinthemanagementofchronickidneydisease
AT młynarskaewelina noveltherapeuticapproachesinthemanagementofchronickidneydisease
AT ryszjacek noveltherapeuticapproachesinthemanagementofchronickidneydisease
AT franczykbeata noveltherapeuticapproachesinthemanagementofchronickidneydisease